BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Solid Tumor|Advanced Breast Cancer|Metastatic Breast Cancer|Hormone-receptor-positive Breast Cancer|Hormone Receptor Positive Breast Carcinoma|Hormone Receptor Positive Malignant Neoplasm of Breast|HER2-negative Breast Cancer|Hormone Receptor Positive HER-2 Negative Breast Cancer|Non-small Cell Lung Cancer
Interventions: DRUG: BGB-43395|DRUG: Fulvestrant|DRUG: Letrozole
Sponsor: BeiGene